Tempus AI (NASDAQ:TEM) Shares Up 14.9% – Should You Buy?

Tempus AI, Inc. (NASDAQ:TEM) shot up 14.9% on Thursday . The company traded as high as $85.71 and last traded at $84.90. 15,252,055 shares traded hands during mid-day trading, an increase of 18% from the average session volume of 12,909,801 shares. The stock had previously closed at $73.88.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on TEM. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Guggenheim began coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Wolfe Research began coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. William Blair cut shares of Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday. Finally, TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Trading Up 14.8 %

The business’s 50-day moving average price is $45.21 and its two-hundred day moving average price is $49.73. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling

In other Tempus AI news, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total value of $25,922.20. Following the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 80,388 shares of Tempus AI stock in a transaction on Friday, February 7th. The shares were sold at an average price of $67.53, for a total transaction of $5,428,601.64. Following the completion of the sale, the chief executive officer now owns 5,293,005 shares in the company, valued at $357,436,627.65. The trade was a 1.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,229,449 shares of company stock worth $102,293,124 over the last ninety days.

Institutional Trading of Tempus AI

Hedge funds and other institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in shares of Tempus AI in the 4th quarter valued at approximately $3,757,000. Legal & General Group Plc raised its position in shares of Tempus AI by 40.6% in the 4th quarter. Legal & General Group Plc now owns 358,432 shares of the company’s stock valued at $12,101,000 after buying an additional 103,464 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Tempus AI by 157.7% in the 4th quarter. Envestnet Asset Management Inc. now owns 44,119 shares of the company’s stock valued at $1,489,000 after buying an additional 26,998 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after buying an additional 278 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Tempus AI in the 4th quarter valued at approximately $1,916,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.